47 related articles for article (PubMed ID: 38696390)
1. Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile.
Zeng Z; Roobrouck A; Deschamps G; Bonnevaux H; Guerif S; De Brabandere V; Amara C; Dejonckheere E; Virone-Oddos A; Chiron M; Konopleva M; Dullaers M
Blood Adv; 2024 May; 8(9):2059-2073. PubMed ID: 38266153
[TBL] [Abstract][Full Text] [Related]
2. Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform.
Al-Hussaini M; Rettig MP; Ritchey JK; Karpova D; Uy GL; Eissenberg LG; Gao F; Eades WC; Bonvini E; Chichili GR; Moore PA; Johnson S; Collins L; DiPersio JF
Blood; 2016 Jan; 127(1):122-31. PubMed ID: 26531164
[TBL] [Abstract][Full Text] [Related]
3. Small-molecule-mediated control of the anti-tumour activity and off-tumour toxicity of a supramolecular bispecific T cell engager.
Gong N; Han X; Xue L; Billingsley MM; Huang X; El-Mayta R; Qin J; Sheppard NC; June CH; Mitchell MJ
Nat Biomed Eng; 2024 May; 8(5):513-528. PubMed ID: 38378820
[TBL] [Abstract][Full Text] [Related]
4. Bispecific T cell engager-armed T cells targeting integrin ανβ6 exhibit enhanced T cell redirection and antitumor activity in cholangiocarcinoma.
Suwanchiwasiri K; Phanthaphol N; Somboonpatarakun C; Yuti P; Sujjitjoon J; Luangwattananun P; Maher J; Yenchitsomanus PT; Junking M
Biomed Pharmacother; 2024 Jun; 175():116718. PubMed ID: 38744221
[TBL] [Abstract][Full Text] [Related]
5. Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing.
Appelbaum J; Price AE; Oda K; Zhang J; Leung WH; Tampella G; Xia D; So PP; Hilton SK; Evandy C; Sarkar S; Martin U; Krostag AR; Leonardi M; Zak DE; Logan R; Lewis P; Franke-Welch S; Ngwenyama N; Fitzgerald M; Tulberg N; Rawlings-Rhea S; Gardner RA; Jones K; Sanabria A; Crago W; Timmer J; Hollands A; Eckelman B; Bilic S; Woodworth J; Lamble A; Gregory PD; Jarjour J; Pogson M; Gustafson JA; Astrakhan A; Jensen MC
J Clin Invest; 2024 Mar; 134(9):. PubMed ID: 38502193
[TBL] [Abstract][Full Text] [Related]
6. FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer.
Mullard A
Nat Rev Drug Discov; 2024 May; ():. PubMed ID: 38789515
[No Abstract] [Full Text] [Related]
7. Author Correction: Small-molecule-mediated control of the anti-tumour activity and off-tumour toxicity of a supramolecular bispecific T cell engager.
Gong N; Han X; Xue L; Billingsley MM; Huang X; El-Mayta R; Qin J; Sheppard NC; June CH; Mitchell MJ
Nat Biomed Eng; 2024 May; 8(5):664. PubMed ID: 38491330
[No Abstract] [Full Text] [Related]
8. CD33 directed bispecific antibodies in acute myeloid leukemia.
Clark MC; Stein A
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101224. PubMed ID: 33279180
[TBL] [Abstract][Full Text] [Related]
9. Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia.
Guy DG; Uy GL
Curr Hematol Malig Rep; 2018 Dec; 13(6):417-425. PubMed ID: 30280288
[TBL] [Abstract][Full Text] [Related]
10. Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564, a bivalent bispecific CD33 x CD3 T cell engager.
Eissenberg LG; Ritchey JK; Rettig MP; Patel DA; Vij K; Gao F; Smith V; Han TH; DiPersio JF
PLoS One; 2024; 19(5):e0300174. PubMed ID: 38696390
[TBL] [Abstract][Full Text] [Related]
11. Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.
Reusch U; Harrington KH; Gudgeon CJ; Fucek I; Ellwanger K; Weichel M; Knackmuss SH; Zhukovsky EA; Fox JA; Kunkel LA; Guenot J; Walter RB
Clin Cancer Res; 2016 Dec; 22(23):5829-5838. PubMed ID: 27189165
[TBL] [Abstract][Full Text] [Related]
12. Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma.
Cheng P; Chen X; Dalton R; Calescibetta A; So T; Gilvary D; Ward G; Smith V; Eckard S; Fox JA; Guenot J; Markowitz J; Cleveland JL; Wright KL; List AF; Wei S; Eksioglu EA
Mol Ther; 2022 Jun; 30(6):2315-2326. PubMed ID: 35150889
[TBL] [Abstract][Full Text] [Related]
13. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia.
Friedrich M; Henn A; Raum T; Bajtus M; Matthes K; Hendrich L; Wahl J; Hoffmann P; Kischel R; Kvesic M; Slootstra JW; Baeuerle PA; Kufer P; Rattel B
Mol Cancer Ther; 2014 Jun; 13(6):1549-57. PubMed ID: 24674885
[TBL] [Abstract][Full Text] [Related]
14. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.
Laszlo GS; Gudgeon CJ; Harrington KH; Dell'Aringa J; Newhall KJ; Means GD; Sinclair AM; Kischel R; Frankel SR; Walter RB
Blood; 2014 Jan; 123(4):554-61. PubMed ID: 24311721
[TBL] [Abstract][Full Text] [Related]
15. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct.
Aigner M; Feulner J; Schaffer S; Kischel R; Kufer P; Schneider K; Henn A; Rattel B; Friedrich M; Baeuerle PA; Mackensen A; Krause SW
Leukemia; 2013 Apr; 27(5):1107-15. PubMed ID: 23178753
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]